Binder replaces William Hawkins, the former Medtronic (NYSE:MDT) chief executive who took the reins at Immucor in 2011. Hawkins will assume the role of lead director on Immucor’s board, that company said.
Immucor is owned by private equity player TPG Capital.
“Immucor is an innovative market leader that is revolutionizing transfusion and transplant medicine, and I look forward to the opportunity to work with the excellent management team and employees to further capitalize on market opportunities,” Binder said in prepared remarks. “I’ve thoroughly enjoyed working with the TPG team during my tenure at Biomet, and know that together we can form another successful partnership at Immucor.”
“It was a privilege to lead the talented team at Immucor and I am very proud of what we have accomplished in our time together,” Hawkins added. “Immucor is in good hands with Jeff at the helm and I look forward to working with Jeff and the board in my new role as lead director to ensure Immucor’s continued success.”
“Jeff joins Immucor with a wealth of experience and a proven track record of success in the healthcare industry. Having worked with Jeff over the past 8 years, we believe he is 1 of the most talented executives in healthcare and is uniquely qualified to lead Immucor into its next chapter of growth. We are pleased that Jeff will also serve as a senior advisor to TPG Capital,” TPG Capital North America managing partner Todd Sisitsky said in a statement. “We are extremely grateful to Bill for his leadership of Immucor over the past 4 years. During Bill’s tenure, the company has expanded globally, entered transplant medicine, resolved the legacy FDA NOIR, introduced breakthrough molecular technologies, and built a rich pipeline of diagnostic assays and systems. We are pleased that he will remain with the company as lead director and look forward to continuing to benefit from his experience and insight.”
Essex Woodlands partner Elias is BD’s new strategy veep
Becton Dickinson & Co. (NYSE:BDX) reportedly lured Tamara Elias, a partner at venture capital firm Essex Woodlands, to be its new vice president of corporate strategy & business development.
Insulet COO, chief counsel are out in corporate shuffle
Insulet (NSDQ:PODD) said last week that COO Patrick Ryan resigned “to pursue other interests,” saying it promoted Mark Licari to vice president of global manufacturing & operations and hired ex-Covidien executive David Colleran as vice president & general counsel, replacing Anthony Diehl, who also resigned.
“On behalf of the Insulet board and management team, I would like to thank Tony and Patrick for their respective contributions to Insulet and wish them both well in their future endeavors,” president & CEO Patrick Sullivan said in prepared remarks. “Looking forward, we are excited to leverage the new leadership team’s extensive experience and long track records of individual career success.”